Point Nemo Capital LLC Buys 79,902 Shares of Takeda Pharmaceutical Co. $TAK

Key Points

• Point Nemo Capital initiated a position in Takeda Pharmaceutical, purchasing 79,902 shares worth approximately $1.45 million in the third quarter.
• Analyst sentiment is broadly positive: MarketBeat reports an average Buy rating, with one Strong Buy, two Buy, and one Hold recommendation.
• Takeda shares opened at $21.02, near their 12-month high of $21.73. Insiders have sold 683,074 shares worth about $12.14 million over the past 90 days.

Point Nemo Capital LLC bought a new stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 79,902 shares of the company's stock, valued at approximately $1,453,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TAK. Renaissance Technologies LLC boosted its position in shares of Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company's stock worth $55,358,000 after acquiring an additional 370,800 shares in the last quarter. Quantinno Capital Management LP increased its holdings in shares of Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company's stock valued at $23,878,000 after acquiring an additional 219,999 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company's stock valued at $11,386,000 after acquiring an additional 60,725 shares during the last quarter. Ethic Inc. raised its position in shares of Takeda Pharmaceutical by 19.5% during the 3rd quarter. Ethic Inc. now owns 436,514 shares of the company's stock worth $7,940,000 after acquiring an additional 71,261 shares in the last quarter. Finally, Bleakley Financial Group LLC raised its position in shares of Takeda Pharmaceutical by 19.0% during the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company's stock worth $7,993,000 after acquiring an additional 68,844 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TAK has been the subject of several recent analyst reports. Zacks Research upgraded Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Finally, Weiss Ratings upgraded shares of Takeda Pharmaceutical from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy".

Insider Activity at Takeda Pharmaceutical

In other Takeda Pharmaceutical news, insider Giles Platford sold 55,617 shares of the firm's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $20.90, for a total transaction of $1,162,395.30. Following the transaction, the insider owned 270,253 shares of the company's stock, valued at approximately $5,648,287.70. This trade represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Plump sold 165,393 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $2,828,220.30. Following the sale, the insider owned 766,569 shares in the company, valued at $13,108,329.90. This trade represents a 17.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 683,074 shares of company stock valued at $12,143,571. Corporate insiders own 0.04% of the company's stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $21.02 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $13.56 and a 12 month high of $21.73. The firm has a market capitalization of $67.35 billion, a P/E ratio of 27.65 and a beta of -0.02. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.15 and a quick ratio of 0.60. The company's fifty day moving average price is $19.12 and its 200 day moving average price is $17.67.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.

The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Takeda serves patients and healthcare providers in Japan and markets around the world.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.